02:25am Intervacc: In the right direction – Q2 review AQ
08-20 Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-20 Intervacc (Q2 initial take): Few surprises – all eyes on the label extension AQ
07-30 Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac CI
07-30 Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration MT
07-30 Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac AQ
07-29 Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand MT
07-29 Intervacc: New Zealand order validates Strangvac’s position AQ
07-29 Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit CI
07-29 Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit AQ
06-04 Redeye initiates coverage of Intervacc AQ
05-22 Intervacc: Positive results AQ
05-22 Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials AQ
05-22 Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials CI
05-15 Intervacc: US progress, while European sales still soft – Q1 review AQ
05-15 Sweden's Intervacc Elects New Chair MT
05-15 Appoints Emil Billbäck as chairman RE
05-15 Emil Billbäck appointed new Chair of the Board of Intervacc AQ
05-13 Intervacc elects Emil Billbäck as chairperson of board RE
05-13 Report from Annual General Meeting in Intervacc AQ
05-13 Intervacc AB Announces Board Changes CI
05-13 Intervacc Q1 net sales down at SEK 3.4 million RE
05-13 Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-12 Intervacc strengthens management team for future growth AQ
05-12 Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026 CI
No results match your criteria